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should be considered for patient eligibility, when PFS is 
used as a surrogate primary endpoint for OS in randomized 
clinical trials of first-line treatment for patients with 
advanced nSClC.
Keywords Meta-analysis · Overall survival · 
Progression-free survival · Post-progression survival ·  
non-small cell lung cancer
Introduction
lung cancer is the leading cause of cancer death world-
wide, and most lung cancers are non-small cell lung can-
cer (nSClC) (Jemal et al. 2010). More than half of all 
nSClCs are diagnosed at an advanced stage; therefore, 
prognosis is often poor (national Cancer Institute 2013). In 
recent decades, platinum-based doublet chemotherapy has 
been used as first-line treatment for patients with advanced 
nSClC (Hotta et al. 2004; lilenbaum et al. 2005; 
D’addario et al. 2005; azzoli et al. 2009). However, such 
treatment is associated with only modest improvements in 
overall survival (OS) and quality of life (QOl) (Schiller 
et al. 2002; Rajeswaran et al. 2008). new treatment strat-
egies, particularly the introduction of molecular-targeted 
agents and appropriate patient selection based on histol-
ogy and/or genotyping, have resulted in marked progress 
in recent years, and OS in advanced nSClC patients has 
improved (Ramalingam et al. 2011; Kobayashi and Hagi-
wara 2013; Kaneda et al. 2013). although there are reports 
in the literature of OS of over 24 months (arrieta et al. 
2010; Maemondo et al. 2010; niho et al. 2012), currently 
available treatments are not able to cure; attempts to find 
a curative treatment are ongoing (Black and Morris 2012; 
Berardi et al. 2013; Bayraktar and Rocha-lima 2013).
Abstract 
Purpose new treatment strategies, particularly the intro-
duction of molecular-targeted agents and appropriate 
patient selection based on histology and/or genotyping, 
have progressed markedly in recent years, and the over-
all survival (OS) in advanced non-small cell lung cancer 
(nSClC) patients has improved. the aim of the study was 
to identify factors affecting longer OS than that estimated 
from progression-free survival (PFS) in first-line treatment 
for advanced nSClC.
Methods Sixty-five controlled trials for first-line treat-
ment of advanced nSClC were extracted for the study. 
Factors influencing higher than predicted OS were exam-
ined by logistic regression analysis between the OS-
extended group and the OS-association group.
Results PFS was moderately associated with OS. twenty 
arms of 14 trials were categorized as an OS-extended 
group, in which the ratio of observed OS to estimated OS 
was found to be over 1.2. On multivariate logistic regres-
sion analysis, number of patients lower than 150, average 
age younger than 63 years, and percentage of squamous 
carcinoma <30 % were found to significantly affect this 
relationship.
Conclusion We identified number of patients and well-
known prognostic factors including age and histological 
cancer type as factors influencing longer OS. these factors 
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OS is the gold standard endpoint for clinical trials 
assessing the efficacy of new drugs for the treatment of 
nSClC (Food Drug administration 2011). OS is defined 
as the time from random assignment of the first treatment 
to death. Measuring OS as an endpoint in clinical trials 
requires large number of patients and increasing longer 
follow-up, thus potentially increasing the cost of devel-
opment and delaying time to approval. additional issues 
with OS as an endpoint include the confounding impact 
of therapies given upon progression, and death not related 
to cancer (garon 2012). Progression-free survival (PFS) 
has become an accepted alternate endpoint in assessing 
efficacy in advanced nSClC (Food Drug administration 
2011; garon 2012; Johnson et al. 2011). However, there 
are examples of improvement in PFS without an OS ben-
efit (lima et al. 2009), and an OS benefit without PFS 
improvement (Cheema and Burkes 2013). Recent well-
developed multiple lines of therapies for advanced nSClC 
patients after progression with first-line treatment have 
been increasing post-progression survival (PPS). Moder-
ate to large improvement in PPS has resulted in reducing 
or losing an OS benefit in comparative clinical trials of 
first-line treatment, even though significant PFS benefit is 
elucidated (lima et al. 2009). therefore, PFS is probably 
the only rational endpoint for the current clinical trials, par-
ticularly in crossover design (Booth and eisenhauer 2012; 
Mok 2011).
Hotta et al. (2011) and Hayashi et al. (2012) reported 
that PPS was highly associated with OS in first-line chem-
otherapy for advanced nSClC, whereas the correlation 
between PFS and OS was moderate. this relationship was 
also found in second- and third-line chemotherapy for 
advanced nSClC (Hayashi et al. 2013). PPS may be one 
of the factors reducing the OS benefit, but little is known 
regarding what factors other than PPS affect the association 
between OS and PFS. the aim of the present study was to 
identify factors affecting the association between OS and 
PFS, particularly those causing longer OS than that esti-
mated based on PFS.
Materials and methods
trial selection and database construction
Controlled trials for first-line treatment of advanced 
nSClC published between January 1, 2003 and December 
31, 2012 were identified through a systemic search of Pub-
Med. Keywords used were “controlled clinical trial,” “first-
line treatment” and “nSClC.” the results were limited to 
articles published in english.
all retrieved abstracts were reviewed in accordance with 
pre-specified inclusion and exclusion criteria. Included 
studies were randomized phase II or III clinical trials of 
first-line therapy of advanced nSClC that presented results 
for both OS and either PFS or time to progression (ttP). 
Studies were excluded if the treatment was adjuvant, 
maintenance or second-line therapy. Studies that investi-
gated only immunotherapy regimens and those that were 
designed to assess combined modality treatment includ-
ing radiation therapy and surgery were also excluded. to 
avoid bias, two observers (Ma and MK) independently 
abstracted the data from the articles.
Data abstraction
abstract data included publication year and reference, 
patient characteristics (age, gender, race, eastern Coopera-
tive Oncology group Performance Status (PS), disease stage, 
histological type of nSClC, smoking history, and geno-
type), treatment information (chemotherapy and/or molecu-
lar-targeted regimen), trial characteristics (study phase, study 
period, region (with/without asian countries), number of 
countries, number of sites, and number of patients), and effi-
cacy information (median months, PFS, ttP, OS). Percent-
ages of males, PS 1, disease stage IV, and squamous cell car-
cinoma were used as variables for gender, PS, disease stage, 
and histological type of nSClC, respectively. OS and either 
PFS or ttP were determined for all the treatment arms using 
published data or survival curves. PFS and ttP were col-
lectively referred to as PFS in order to increase the sample 
size as done previously in recent reports (26,27). PPS was 
defined as OS minus PFS for each trial.
Data analysis
to assess the correlation between OS and either PFS or 
PPS, we used Spearman’s rank correlation coefficient (r). 
We conducted a simple linear regression analysis to obtain 
a regression line between PFS and OS and calculated the 
estimated OS from the PFS based on the regression equa-
tion. according to the ratio of observed OS/estimated OS, 
the treatment arms were classified into three groups: <0.8 
(OS-reduced group), 0.8–1.2 (OS-association group), and 
>1.2 (OS-extended group). Factors influencing higher and 
lower than predicted OS were initially examined by univar-
iate logistic regression analysis using a fixed-effect model 
between the OS-extended group and the OS-association 
group as well as the OS-reduced group and the OS-associ-
ation group. after identifying potential influencing factors, 
multivariate logistic regression analysis was conducted in a 
stepwise fashion to further investigate factors that contrib-
ute to OS extension. a p < 0.05 was considered statistically 
significant throughout the analyses except where otherwise 
noted. the analyses were conducted using StatsDirect soft-
ware (ver. 2.7.9; StatsDirect ltd. UK).
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Results
Characteristics of the trials
a total 175 potentially relevant trials were identified. Initially, 
46 trials were excluded for at least one of the following rea-
sons: other malignancies, non-randomized, phase I/II, review 
articles, combination analyses, subgroup analyses, and dupli-
cate references. a further, 46 trials were excluded because the 
trials were in a second-line setting or involved maintenance 
therapy after first-line treatment. Finally, after excluding trials 
without information on the necessary endpoints (OS, PFS or 
ttP) or patient baseline characteristics, 65 trials were consid-
ered to be highly relevant for the present study. the selection 
process for the randomized controlled trials is shown in Fig. 1.
the main characteristics of the 65 trials are listed in 
table 1. a total of 140 treatment arms and 23,337 patients 
with advanced nSClC were included. the median of the 
number of patients per trial was 70.5 (range 20–863) with 
most trials having a high proportion of males (71.0 %: range 
20.5–95.7 %). the average median age was 61.1 years (range 
56–78). among 140 treatment arms, there were 86 chemo-
therapy arms, 7 molecular-targeted therapy arms, and 47 com-
bination therapy arms. eighty three arms were from phase II 
trials and 57 from III trials. trials were classified into two 
groups by the year of start of the trial, considering the tim-
ing of the introduction of molecular-targeted agents: between 
1998 and 2003 (59 arms), and between 2004 and 2008 (67 
arms). the median OS was 9.9 months (range 3.5–30.5), and 
median PFS was 5.0 months (range 1.7–10.8) for all arms. 
Information of the number of participating counties and the 
race of trial subjects was very limited. there was limited data 
on genotyping of nSClC and treatment after progression. 
Relation between OS and either PFS or PPS
the relation between OS and either PFS or PPS for the 
140 arms is shown in Fig. 2. PPS was strongly associated 
with OS (Spearman’s r = 0.841, p < 0.0001), whereas 
PFS was more moderately associated with OS (r = 0.689, 
p < 0.0001). the regression line between OS and PFS was:




Fig. 1  Flow chart showing the 
progress of trials through the 
review




Potentially appropriate trials to be 
included in the study (n=83)
Trials with adequate information
(n=65)
Trials excluded (n=46)
Reason: other malignancies, 
nonrandomized trials, phase I/II trials, 
review articles, combined analyses, 
subgroup analyses, duplicate references 
Trials excluded (n=46)
Reason: trials in second-line setting or 
maintenance therapy after first-line setting   
Trials excluded (n=18)
Reason: trials without information on time 
end points (OS or PFS) or baseline patient 
characteristics   
Table 1  Characteristics of 140 treatment arms in the 65 trials
Variables Overalls
total number of trials 65
total number of arms 140
total number of patients 23,337
treatment
 Chemotherapy 86 (61.4 %)
 Molecular target therapy 7 (5.0 %)
 Combination therapy 47 (33.6 %)
Phase
 II 83 (59.3 %)
 III 57 (40.7 %)
Study period
 1998–2003 59 (42.1 %)
 2004–2008 67 (47.9 %)
 Unknown 14 (10.0 %)
Region
 Including asian countries 20 (14.3 %)
 Without asian countries 55 (39.3 %)
 Unknown 65 (46.4 %)
number of sites (n = 65) 55.0 (3–200)
average of age (n = 136) 62.8 (56.0–78.0)
Percentage of male patients (n = 140) 69.1 (20.5–95.7)
Percentage of patients with PS 1 (n = 113) 56.0 (0–83.0)
Percentage of patients with stage IV (n = 128) 81.2 (44.0–98.0)
Percentage of patients with squamous cell  
carcinoma (n = 128)
26.4 (0–64.0)
Percentage of smoker (n = 55) 70.7 (6.3–100)
OS (months) (n = 140) 10.6 (3.5–30.5)
PFS (months) (n = 140) 5.0 (1.7–10.8)
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Table 2  Characteristics of each category classified by the ratio of observed OS/estimated OS
Ratio of OS observed/estimated OS p valuea
Reduced group association group extended group
<0.8 0.8–1.2 >1.2
total of trials 18 53 14
total of arms 26 94 20
total of patients 2,576 18,271 2,490
treatment
 Chemotherapy 15 (57.0 %) 60 (63.8 %) 11 (55.0 %) 0.459
 Othersb 11 (43.0 %) 34 (36.2 %) 9 (45.0 %)
Phase
 II 18 (69.2 %) 48 (51.1 %) 17 (85.0 %) 0.005
 III 8 (30.8 %) 46 (48.9 %) 3 (15.0 %)
Study period
 1998–2003 17 (65.4 %) 33 (35.1 %) 6 (30.0 %) 0.459
 2004–2008 9 (34.6 %) 48 (51.1 %) 13 (65.0 %)
 Unknown 0 13 (13.8 %) 1 (5.0 %)
Region
 Including asian countries 0 (0.0 %) 11 (11.7 %) 9 (45.0 %) 0.001
 Without asian countries 13 (50.0 %) 38 (40.4 %) 4 (20.0 %)
 Unknown 13 (50.0 %) 45 (47.9 %) 7 (35.0 %)
number of sites per trial 18.2 69.9 31.0
 <30 7 15 9 0.028
 ≧30 2 28 4
number of patients per arm 99.1 194.4 124.5
 <150 21 51 17 0.011
 ≧150 5 43 3
average of age (year) 65.1 62.9 59.7
 <63 year 14 55 16 0.014
 ≧63 year 10 39 2
Percentage of male patientsc 72.7 % 70.9 % 56.1 %
 <70 % 10 35 15 0.002
 ≧70 % 16 59 5
Percentage of patients with PS 1c 53.2 % 56.9 % 55.0 %
 <60 % 14 40 8 0.442
 ≧60 % 3 37 11
Percentage of patients with stage IVc 83.1 % 81.2 % 78.8 %
 <80 % 5 32 11 0.097
 ≧80 % 18 54 8
Percentage of patients with squamous cell 
carcinomac
28.8 % 28.4 % 12.6 %
 <30 % 13 46 16 0.002
 ≧30 % 12 40 1
Percentage of smokersc 63.9 % 76.2 % 57.6 %
 <70 % 2 4 9 <0.001
 ≧70 % 3 33 4
OS (months) 7.9 10.0 16.6
PFS (months) 5.2 4.9 5.2
a
 p value was obtained by chi-square test between the OS-association group and the OS-extended group (>1.2)
b
 Others consists of molecular-targeted agents and the combination of chemotherapy and molecular-targeted agents
c
 Percentage per arm
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Characteristics of the OS-extended group
Based on the ratio of the observed OS to the estimated 
OS, we classified the treatment arms into three groups: 
OS-reduced group (ratio: <0.8), OS-association group 
(ratio: 0.8–1.2), and OS-extended group (ratio: >1.2). 
Characteristics of the three groups are summarized in 
table 2. there were 20 arms (14.3 %) from 14 trials in 
the OS-extended group (arrieta et al. 2010; Maemondo 
et al. 2010; niho et al. 2012; Hirsch et al. 2011; Park et al. 
2007; Mok et al. 2009a, b; Heymach et al. 2008; grossi 
et al. 2012; gridelli et al. 2007; gebbia et al. 2010; Chen 
et al. 2007; lilenbaum et al. 2008; Ramlau et al. 2008; 
table 3). the range of the observed OS/estimated OS 
ratio was 1.22–2.75. In the OS-association group, there 
were 94 arms of 53 trials, and in the OS-reduced group, 
there were 26 arms of 18 trials. after excluding the arms 
from the OS-extended group, the correlation between OS 
and PFS improved (Spearman’s r = 0.789, Supplement 
Figure 1).
Statistically significant differences on univariate logistic 
regression analysis between the OS-association group and 
the OS-extended group were found in the following vari-
ables: study phase, area, region, number of sites per trial, 
number of patients per arm, average age, the proportion of 
males, percentage of squamous cell carcinoma, and smok-
ing history (table 2).
exclusion of arms from the OS-reduced group did not 
improve correlation between OS and PFS. therefore, fur-
ther analysis of the OS-reduced group was not conducted.
Identification of factors influencing OS extended
We selected types of drugs (chemotherapeutic agent, oth-
ers), study period (1998–2003, 2004–2008), number of 
patients (<150, ≥150), average age (<63, ≥63), percentage 
of male (<70, ≥70), percentage of patients with PS1 <60, 
≥60), percentage of patients with stage IV disease (<80, 
≥80), and percentage of patients with squamous cell carci-
noma (<30, ≥30) as potential influencing factors (Supple-
ment table 1). the number of arms, for which information 
about region, number of sites, and smoking history was 
small, was excluded from the logistic regression analyses.
On univariate logistic regression analyses using these 
potential factors, we identified variables such as number of 
patients, average age, percentage of males, and histological 
cancer type as factors potentially influencing extension of 
OS with statistically significant association (table 4). On 
further multivariate logistic regression analyses, number of 
patients less than 150 per study arm, average age younger 
than 63 years, and percentage of patients in the study arm 
with squamous cell carcinoma of <30 % were identified as 
statistically significant influencing factors for extended OS 
as shown in table 4.
Discussion
new treatment strategies, particularly the introduction of 
molecular-targeted agents and appropriate patient selec-
tion based on histology and/or genotyping, have progressed 
markedly in recent years, and the OS in advanced nSClC 
patients has improved (Ramalingam et al. 2011; Kobayashi 
and Hagiwara 2013; Kaneda et al. 2013). there are now 
examples of improvement in PFS without an OS benefit 
(lima et al. 2009), and an OS benefit without PFS improve-
ment (Cheema and Burkes 2013). Recent well-developed 
Fig. 2  Correlation between Overall Survival (OS) and either (a) Pro-
gression-Free Survival (PFS) or (b) Post-Progression Survival (PPS) 
for 140 arms of 65 clinical trials for first-line treatment for patients 
with advanced nSClC. the coefficients of correlation (r) between 
OS either PFS or PPS were 0.662 and 0.935, respectively. the size of 
each circle is proportion to the number of patients in the correspond-
ing arm
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multiple lines of therapies for advanced nSClC patients 
after progression with first-line treatment have been associ-
ated with an increase in PPS.
We confirmed that OS was more strongly associated with 
PPS than with PFS among 140 arms of 65 phase II and III 
clinical trials for first-line treatment of advanced nSClC. 
Our results are similar to those previously reported (Hotta 
et al. 2011; Hayashi et al. 2012). these strong associations 
between PPS and OS have also been shown in the first-line 
treatment of advanced colorectal (Petrelli and Barni 2013) 
and breast cancers (Saad et al. 2010a, b).
Broglio et al. demonstrated that PPS has an important 
impact on the association between PFS and OS (Broglio 
and Berry 2009). When PPS is short, PFS benefit results 
in a statistically significant OS benefit; however, moderate 
to longer PPS results in reducing or losing an OS benefit 
in comparative clinical trials of first-line treatment, even if 
a significant difference in PFS is observed in randomized 
trials. If using OS as the primary endpoint, subsequent mul-
tiple treatments after the experimental treatment should be 
considered in clinical trial design (collecting data or defin-
ing subsequent treatment options) because PPS may be a 
potential confounding factor. However, none of the reports 
we reviewed mentioned these details.
Improving OS remains the gold standard of clinical tri-
als. However, when OS benefit is diluted and masked by 
longer PPS, OS may not be the most appropriate primary 
endpoint for assessing the clinical effect for first-line treat-
ment. although PFS is not a very good surrogate of OS, 
particularly when PPS is long, PFS should be considered 
as an attractive endpoint, because it is available earlier than 
OS, is less influenced than OS by competing causes of 
death, and is not influenced by PPS. notably, in advanced 
breast cancer, there have been few phase III trials where 
OS was used as the primary endpoint (Verma et al. 2011). 
It has become increasingly common for PFS or ttP to be 
used as a primary endpoint in recent phase III randomized 
trials of first-line treatment for advanced breast cancer 
(Saad et al. 2010a, b; Saad and Katz 2009) and metastatic 
colorectal cancer (Saad et al. 2010a). In these cancers, it is 
well known that subsequent line of therapy plays a major 
role in determining OS (Saad et al. 2010a, b; tang et al. 
2007; Chirila et al. 2012).
In advanced nSClC, PFS has not been accepted as a 
surrogate for OS (laporte et al. 2013). However, the US 
Food and Drug administration has a draft guidance regard-
ing the use of PFS as a clinical endpoint, which is likely 
to be accepted if the observed magnitude of effect is sub-
stantial and robust (Food Drug administration 2011). the 
recent progress of multi-line treatment after first-line treat-
ment for advanced nSClC has provided longer PPS, which 
resulted in a reduced OS benefit as the primary endpoint, 
as already seen in advanced breast and colorectal cancers 
(Cufer et al. 2013), and PFS is a common primary endpoint 
in current randomized clinical trials. a search in clinical 
trial databases by Soria et al. (2010) found that more than 
150 trials use PFS as the primary endpoint in stage III/IV of 
nSClC. Schrimpf et al. (2013) proposes that PFS with the 
addition of some measures like patient-reported outcomes 
such as QOl and/or treatment toxicity could cover the 
clinical benefit in nSClC studies for individualized thera-
pies with clear patient selection. Mandrekar et al. (2010) 
reported that PFS or failure-free survival at 12 weeks was 
a stronger predictor of subsequent patient survival than 
Table 4  Influencing factors identified by univariate and multiple analysis for the OS-extended group
OR odds ratio
Characteristics Category Univariate analysis Multivariate analysis
OR 95 % CI p value OR 95 % CI p value
treatments Chemo only others 1.444 0.544–3.833 0.461 – – –
Study period 1998–2003
2004–2008
1.567 0.541–4.538 0.408 – – –
number of patients <150
≥150
0.209 0.057–0.762 0.018 0.045 0.007–0.308 0.002
average of age (year) <63,
≥63
0.176 0.038–0.811 0.026 0.087 0.010–0.770 0.028
Percentage of male patients (%) <70
≥70
0.198 0.066–0.591 0.004 0.218 0.038–1.237 0.086
Percentage of patients with PS 1 (%) <60
≥60
1.486 0.539–4.100 0.444 – – –
Percentage of patients with stage IV disease (%) <80
≥80
0.431 0.157–1.184 0.103 0.243 0.051–1.166 0.077
Percentage of patients with squamous cell carcinoma (%) <30
≥30
0.072 0.009–0.566 0.012 0.074 0.007–0.799 0.032
846 J Cancer Res Clin Oncol (2014) 140:839–848
1 3
tumor response and proposed that this be used routinely as 
an endpoint in phase II trials for advanced nSClC. this 
could lead to more accurate assessment of the true efficacy 
of new drugs for advanced nSClC.
Our meta-analysis with moderate association between 
PFS and OS suggests that PFS is not an appropriate sur-
rogate for OS. We conducted subgroup analysis to identify 
factors associated with the longer OS than that estimated 
from PFS. among 65 trials, we identified 20 arms of 14 
trials as the OS-extended group, wherein the observed 
OS was 20 % longer than the estimated OS based on 
PFS. When these 20 arms were excluded from the analy-
sis, the correlation between OS and PFS was improved. It 
was noteworthy that there were factors in addition to PPS 
involved in reducing the association. Univariate analysis 
identified four variables significantly relevant to OS exten-
sion (p < 0.05): number of patients (<150/arm), mean age 
(<63 years), percentage of males (<70 %), and histology 
of nSClC (<30 % of squamous cell cancer). Multivari-
ate analysis showed that three of these four variables were 
statistically correlated with OS-extended group: number 
of patients less than 150 per arm, mean age younger than 
63 years and squamous cell cancer <30 %.
the most widely accepted prognosis determinants are 
disease stage and PS (Mountain 1997). Male gender, age 
older than 60 years, non-squamous histology, smoking, 
and weight loss are known to be prognostic factors (Char-
loux et al. 1997). therefore, it is not unexpected that age 
younger than 63 years and squamous cell carcinoma <30 % 
were influencing factors of OS extension in our findings. 
PS is a valid prognostic factor (Belbaraka et al. 2010), but 
was not identified as such in our study. this might be due 
to the fact that mainly PS 0 or PS 1 patients were enrolled 
in most of the clinical trials (PS 2 was only seen in 4.2 % 
of all patients). the percentage of smokers was excluded 
from the regression analyses because of small sample size, 
but this could be expected to have an influence on OS in 
nSClC clinical trials. Interestingly, no effect of molecular-
targeted agents on OS extension was observed, as no statis-
tical significance was observed in either the treatment regi-
men or the period in which the trials were conducted. In 
the OS-extended group, the number of trials in which asian 
counties were involved was significantly greater in the OS-
extended group than in the OS-association group. However, 
this factor was not analyzed further due to limited sample 
size. Participation of asian countries in recent global clini-
cal trials has been increasing, and an affect of region and 
race might be considered in future clinical trials.
When PFS is used as the primary endpoint in phase II 
trial and OS is used in phase III trial, our results suggest 
factors to be considered in protocol design in order to elu-
cidate the true clinical benefit of experimental drugs for 
the first-line treatment of advanced nSClC: (1) increasing 
the number of sites and number of patients which would 
improve the association between OS and PFS, (2) adjust-
ing patient baseline characteristics, particularly relevant to 
prognosis factors both in phase II and phase III trial.
Several technical limitations of our study should be 
acknowledged. First, our study was not based on individu-
als, and many complex conditions were involved. Second, 
there was a limitation in terms of available parameters. 
Conducting trials in asia seemed to influence OS exten-
sion, but small sample size meant this did not provide sta-
tistically significant information. Finally, data on subse-
quent treatment after progression were not available; such 
data may be very important when PPS is considered as a 
potential confounder.
In conclusion, we identified number of patients and 
well-known prognostic factors including age and histo-
logical cancer type as factors influencing longer OS. these 
factors should be considered for patient eligibility, when 
PFS is used as a surrogate primary endpoint for OS in ran-
domized clinical trials of first-line treatment for patients 
with advanced nSClC.
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